- Home
- NVVE vs MYNZ Comparison
NVVE vs MYNZ Comparison
Compare NVVE & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVVE
- MYNZ
- Stock Information
- Founded
- NVVE 1996
- MYNZ 2021
- Country
- NVVE United States
- MYNZ Germany
- Employees
- NVVE N/A
- MYNZ N/A
- Industry
- NVVE Oil Refining/Marketing
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- NVVE Energy
- MYNZ Health Care
- Exchange
- NVVE Nasdaq
- MYNZ Nasdaq
- Market Cap
- NVVE 5.5M
- MYNZ 5.1M
- IPO Year
- NVVE N/A
- MYNZ 2021
- Fundamental
- Price
- NVVE $0.53
- MYNZ $1.52
- Analyst Decision
- NVVE
- MYNZ Buy
- Analyst Count
- NVVE 0
- MYNZ 2
- Target Price
- NVVE N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- NVVE 2.0M
- MYNZ 228.6K
- Earning Date
- NVVE 08-14-2025
- MYNZ 08-12-2025
- Dividend Yield
- NVVE N/A
- MYNZ N/A
- EPS Growth
- NVVE N/A
- MYNZ N/A
- EPS
- NVVE N/A
- MYNZ N/A
- Revenue
- NVVE $5,440,777.00
- MYNZ $893,991.00
- Revenue This Year
- NVVE $892.33
- MYNZ $26.06
- Revenue Next Year
- NVVE N/A
- MYNZ $4.97
- P/E Ratio
- NVVE N/A
- MYNZ N/A
- Revenue Growth
- NVVE N/A
- MYNZ N/A
- 52 Week Low
- NVVE $0.48
- MYNZ $1.30
- 52 Week High
- NVVE $8.76
- MYNZ $18.40
- Technical
- Relative Strength Index (RSI)
- NVVE 31.86
- MYNZ 40.33
- Support Level
- NVVE $0.48
- MYNZ $1.30
- Resistance Level
- NVVE $0.63
- MYNZ $2.07
- Average True Range (ATR)
- NVVE 0.09
- MYNZ 0.19
- MACD
- NVVE -0.02
- MYNZ -0.05
- Stochastic Oscillator
- NVVE 8.57
- MYNZ 21.19
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.